Skip to main content

Advertisement

Combinatorial treatment of acute myocardial infarction using stem cells and their derived exosomes resulted in improved heart performance

Article metrics

  • 491 Accesses

Abstract

Background

Bone marrow mesenchymal stem cells (MSCs) are among the most common cell types to be used and studied for cardiac regeneration. Low survival rate and difficult retention of delivered MSCs in infarcted heart remain as major challenges in the field. Co-delivery of stem cell-derived exosomes (Exo) is expected to improve the recruitment and survival of transplanted MSCs.

Methods

Exo was isolated from MSCs and delivered to an acute myocardial infarction (AMI) rat heart through intramyocardial injection with or without intravenous infusion of atrovastatin-pretreated MSCs on day 1, day 3, or day 7 after infarction. Echocardiography was performed to evaluate cardiac function. Histological analysis and ELISA test were performed to assess angiogenesis, SDF-1, and inflammatory factor expression in the infarct border zone. The anti-apoptosis effect of Exo on MSCs was evaluated using flow cytometry and Hoechst 33342 staining assay.

Results

We found that intramyocardial delivery of Exo followed by MSC transplantation (in brief, Exo+MSC treatment) into MI hearts further improved cardiac function, reduced infarct size, and increased neovascularization when compared to controls treated with Exo or MSCs alone. Of note, comparing the three co-transplanting groups, intramyocardially injecting Exo 30 min after AMI combined with MSCs transplantation at day 3 after AMI achieved the highest improvement in heart function. The observed enhanced heart function is likely due to an improved microenvironment via Exo injection, which is exemplified as reduced inflammatory responses and better MSC recruitment and retention. Furthermore, we demonstrated that pre-transplantation injection of Exo enhanced survival of MSCs and reduced their apoptosis both in vitro and in vivo.

Conclusions

Combinatorial delivery of exosomes and stem cells in a sequential manner effectively reduces scar size and restores heart function after AMI. This approach may represent as an alternative promising strategy for stem cell-based heart repair and therapy.

Introduction

Ischemic heart disease (IHD) is the leading cause of mortality around the world, accounting for 16.6% of all death in 2016 [1]. Stem cell therapy has been recognized as a promising approach for the treatment of IHD via replenishing lost cells after acute myocardial infarction (AMI). Accumulating preclinical studies have shown that transplantation of various types of stem cells, such as bone marrow-derived mononuclear cells (BMMNCs), mesenchymal stem cells (MSCs), circulating progenitor cells (CPCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) and their derivatives improved cardiac function after AMI [2, 3]. However, limited studies achieved significant improvement in cardiac contractile function and scar reduction after AMI due to poor engraftment and survival of transplanted cells in the ischemic heart [2,3,4].

The interaction between stromal cell-derived factor 1 (SDF-1) and its receptor CXC chemokine receptor 4 (CXCR4) has been demonstrated to play a vital role in the recruitment of stem cells to the ischemic myocardium [5,6,7,8]. It has been shown that the expression of SDF-1 in ischemic cardiac tissues is transiently elevated and peaked at 1 to 3 days after ischemic insult and decreases to the background level in the following few days [8,9,10]. Consequently, transplantation of stem cells during early days after AMI achieved higher cell recruitment rate [10]. However, acute inflammatory reaction and highly oxidative stress at the same stage of elevated SDF-1 expression is detrimental for the survival of transplanted cells [11]. Enhancing SDF-1 expression while dampening inflammatory level may help to promote the cell engraftment and survival, thus to improve the subsequent therapeutic efficiency [12, 13].

Exosomes are extracellular, membrane-bound vesicles with a diameter of 30–150 nm and contain a wide range of functional proteins, mRNAs, and microRNAs (miRNAs) [14, 15]. They originate intracellularly and are actively secreted by most cell types. Exosomes play an important role in intercellular and tissue-level communication by transferring their cargo of bioactive molecules between cells. Recent studies suggested that MSC-derived exosomes (Exo) could serve as potential cell-free therapy for cardiac repair with the ability to augment cell survival, proliferation, neovascularization, and ameliorate inflammatory reaction in infarcted heart [16,17,18,19,20]. It remains unclear whether Exo could synergize with stem cells to further improve efficacy of cardiac stem cell transplantation therapy.

In this study, we investigated the therapeutic effects of sequential delivery of Exo and MSCs on rat AMI hearts and explored the optimal time window for the delivery. Exo treatment followed by MSC delivery at early stage after AMI further improved cardiac function and stimulated angiogenesis compared to MSC delivery alone. In particular, MSC injection 3 days after Exo led to reduced inflammatory levels and increased expression of SDF-1, which in turn promoted MSC retention and survival, thereby leading to improved heart performance. Our data thus suggests that sequential delivery of Exo and MSCs may represent as an alternative promising strategy for stem cell-based heart repair and therapy.

Methods

Animal use

All animals were obtained from the Experimental Animal Center of Fuwai Hospital (Beijing, China). All experiments conformed to the National Institute of Health Guide for Care and Use of Laboratory Animals and were approved by the Experimental Animals Ethics Committee of Fuwai Hospital.

Bone marrow MSC isolation and cell culture

MSCs were obtained from male Sprague-Dawley (SD) rats (60–80 g) as previously described [21]. In brief, bone marrow was flushed with medium from the femur and tibia and seeded in culture dishes containing Iscove’s Modified Dulbecco’s Medium (IMDM, Invitrogen) with 10% fetal bovine serum (FBS, Gibco) and penicillin (100 U/mL)/streptomycin (100 μg/mL) (HyClone). After 24 h of culturing at 37 °C in a humidified incubator with 5% CO2, the medium was changed to remove the non-adherent cells. When they grew to about 90% confluence, MSCs were harvested and passaged at a ratio of 1:3. MSCs at passage 3 were identified by flow cytometry with antibodies against the cell surface markers of CD45 (Ebioscience), CD29 (Ebioscience), CD90 (Ebioscience), and CD11 (BD Biosciences). Passage 3–4 MSCs were used in this study.

Exosome extraction and identification

Exosomes were isolated by differential centrifugation as previously described [22]. In brief, MSCs were cultured in exosome-free FBS containing IMDM for 48 h, which was previously centrifuged at 120,000g for 18 h to remove pre-existing bovine-derived exosomes. Then, the conditioned supernatant was collected and centrifuged. Cells and debris were eliminated by centrifugation at 300g for 10 min and 2000g for 20 min respectively, and macrovesicles were removed at 13500g for 30 min. The supernatant continues to be ultracentrifuged at 120,000g for 70 min to obtain the crude exosome pellet. The pellet was subsequently washed with phosphate-buffered saline (PBS, pH 7.4) followed by repeat ultracentrifugation for 70 min at the same speed. The exosome pellet was resuspended in appropriate volume of PBS and stored at − 80 °C for the use in the experiments. The entire operation was performed in sterile condition.

The protein concentrations of Exo were measured by microBCA protein assay kit (Thermo Scientific). Then, the shape and size of exosomes were identified by transmission electron microscope (TEM, HITACHI, H-600IV) and Nanoparticle Tracking Analysis (NTA, Malvern Instruments, UK). In addition, the Exo were identified by using Western blot with antibodies against CD81 (Cell Signaling Technology), CD63 (Cell Signaling Technology), Alix (Cell Signaling Technology), and TSG101 (Cell Signaling Technology), which were previously described as specific exosome markers [14, 23].

Internalization of PKH26-labeled exosomes into MSCs

To determine whether exosomes can be efficiently internalized by MSCs both in vitro and in vivo, purified exosomes were labeled with fluorescent dye PKH26 using Red Fluorescent Cell Linker Kit (Sigma-Aldrich) according to the manufacturer’s protocol and washed in PBS followed by 2 times of ultracentrifugation to remove the extra dye. The PKH26 pre-labeled MSC-derived exosomes (Exo-PKH26, 2 μg/ml) were added into MSCs in culture and incubated for 12 h; then, the cells were washed with PBS, fixed with 4% paraformaldehyde, and stained with fluorescent antibody against smooth muscle α-actin (α-SMA) and DAPI at room temperature. Uptake of labeled exosomes by cells was determined using confocal microscopy. For in vivo experiments, 10 μg pre-labeled exosomes were injected to the border zone of infarcted heart 30 min after infarction. Distribution of Exo-PKH26 in infarcted heart was monitored on day 1, day 3, and day 7 after injection by immunofluorescence, and the photographs were taken under confocal microscopy (LSM 780, Zeiss).

Rat AMI model induction

All surgeries and subsequent analyses were performed in a blinded fashion for intervention. Animals were randomized into different treatment groups. Female Sprague-Dawley rats (200–220 g weight) were anesthetized by intraperitoneal injection of 100 mg/kg ketamine combined with 10 mg/kg xylazine and ventilated via tracheal intubations connected to a rodent ventilator. AMI surgery was performed by ligation of left anterior descending coronary artery with a 6-0 silk suture as described previously [21, 24]. AMI induction was verified by loss of color in the region below the ligation area.

Pretreatment of MSCs and implantation of exosome and MSCs

Our previous study reported that pretreating MSCs with 1 μM atorvastatin (ATV, one of the widely used lipid-lowering drugs for patients with coronary heart disease) for 12 h enhanced the migration of MSCs to the infarct site by increasing the expression of CXCR4 on the surface of MSCs. This improved the homing and survival of MSCs infused through tail vein and improved cardiac function after AMI [21]. Therefore, it is feasible to transplant MSCs through systemic infusion, which will be more convenient for future clinical use. Thus, in this study, all the MSCs were pretreated with 1 μM ATV for 12 h and injected through tail vein.

Rats were randomized into Sham; AMI (PBS alone); Exo (exosomes treatment alone); MSCd1, MSCd3, and MSCd7 (MSCs transplantation alone at d1, d3, d7 post AMI respectively), and Exo+MSCd1, Exo+MSCd3, and Exo+MSCd7 groups (Exo combined with MSCs transplantation at d1, d3, d7 post AMI respectively). The Sham group underwent the same surgical procedures except for the permanent ligation step. Exo (10 μg, in 100 μl PBS) or PBS (AMI group) were injected at three sites around the border zone of infarcted heart 30 min after left anterior descending coronary artery ligation using a 31-gauge Hamilton syringe. For stem cells transplantation groups, 2 × 106 MSCs were injected into the Exo or PBS delivered rats through the tail vein at 1 day, 3 days, or 7 days post AMI. Heart function, infarct area, and angiogenesis were evaluated at 5 weeks post infarction.

Cardiac function

Rats were anesthetized for analysis with a mixture of 1.5% isoflurane and oxygen (0.8 L/min). Transthoracic two-dimensional M-mode echocardiography was performed to evaluate the cardiac function at baseline (3 days post MI) and endpoint (5 weeks post MI) using the Vevo 2000 system (VisualSonics). M-mode were used to measure left ventricular wall thickness and left ventricular inner diameter in systole and diastole. The mean value of three measurements was determined for each sample. The variation of the left ventricular ejection fraction (LVEF), fractional shortening (FS), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) between baseline and endpoint were calculated. All procedures and analysis were conducted by a researcher who was blinded to treatments.

Histological analysis

Five weeks after AMI, animals were euthanized to remove the hearts. Both Masson trichrome staining (Sigma) and Sirius Red staining were used for determining infarct size and fibrosis, and hematoxylin-eosin (HE) staining was performed to evaluate inflammatory cell infiltration. In brief, the hearts were simply trimmed to eliminate the upper part of ligation after immersion in 4% formaldehyde for 48 h. The remainder of the heart was cut at 1 mm below the ligation point perpendicular to the axis of the left anterior descending coronary artery and processed with paraffin embedding. To elucidate the severity of myocardial infarction, the slices with 4 μm of paraffin tissue were stained with Masson trichrome to measure the average ratio of the fibrotic area to the entire LV cross-sectional area (infarct area/LV%), and Sirius Red staining was used to calculate the average ratio of collagen area to entire LV area (collagen area/LV %), with the use of Image J software (Version 1.51j8, NIH) [25,26,27].

Immunohistochemical analysis

To assess angiogenesis and SDF-1 expression in the infarct border zone, the heart tissue sections were deparaffinized, rehydrated, permeabilized, and then stained with conjugated antibodies against CD31 (Abcam), α-SMA (Abcam), or SDF-1 (Santa Cruz). Then, the sections were incubated with respective secondary antibodies conjugated with Alexa fluor 488 (Invitrogen) or color reaction with the DAB kit. The samples were analyzed using a confocal microscope (LSM 780, Zeiss). Positively stained cells were counted in three sections per heart, five high-power fields (HPFs) per section. Vascular density was quantified as the number of CD31+ cells per HPF. Arteriole density was quantified as the number of α-SMA+ cells per HPF. SDF-1 expression in peri-infarcted heart tissue at 1 day, 3 days, and 7 days after AMI was also quantitatively evaluated by rat SDF-1 ELISA kit (Elabscience, E-EL-R0922c) according to the manufacturer’s instructions.

Apoptosis assay

MSCs were plated on 6-well plates (1 × 105 cells/well) and pretreated by PBS or 2 μg/ml of Exo for 12 h, then changed to DMEM without glucose and FBS and induced apoptosis by H/SD condition. Cells were put into a sealed GENbox hypoxic chamber fitted with an AnaeroPack (Mitsubishi Gas Chemical Company, Japan) to scavenge the free oxygen at 37 °C for 10 h. The oxygen concentration was maintained below 0.1% as indicated by an Anaer indicator (Bio-Merieux, Marcy I’ Etoile, France). The anti-apoptosis effect of exosomes on MSCs was evaluated using flow cytometry and Hoechst 33342 staining assay.

Statistical analysis

Data were given as mean ± standard error of mean (SEM). Continuous variables were compared by the Student t test. Multiple comparisons were performed by one-way ANOVA followed by Tukey’s test, two-way ANOVA, or repeated-measure two-way ANOVA followed by Tukey post hoc test. Data was analyzed with SPSS 22 (IBM) or GraphPad Prism 7 for Windows, version 7.01 (GraphPad Software, Inc.). Graphs were assembled in GraphPad Prism 7. P < 0.05 was considered to indicate a significant difference.

Results

Characterization of exosomes derived from MSCs

To obtain sufficient and high-quality exosomes, we enriched exosomes from MSCs derived from rat bone marrow. MSCs at passages 3–4 were typically adherent spindle-shaped cells and were recognized as CD90+ CD29+ CD45− CD11− cells analyzed by flow cytometry (Fig. 1a). Exosomes isolated from MSCs were spheroids or typical cup-shaped vesicles with an average size of ~ 100 nm as visualized using TEM and NTA (Fig. 1b, c). The isolated exosomes contained high level of exosome-specific proteins such as Alix, TSG101, and CD63 (Fig. 1d). PKH26 pre-labeled Exo can be efficiently internalized by co-cultured cells in 12 h and localized in cytoplasm, suggesting they were intact and functional (Fig. 1e). Injection of Exo-PKH26 into injured hearts showed peaked retention of Exo at 24 h after MI, and gradually dropped from day 3 to day 7 (Fig. 1f, g).

Fig. 1
figure1

Characterization and functional validation of exosomes derived from MSCs (Exo). a Phenotypic analysis of cell surface antigens of MSCs by flow cytometry. b Cup-shaped morphology of purified Exo assessed by transmission electron microscopy. Scale bar = 200 nm. c The particle size, particle concentration, and video frame of Exo analyzed by nanoparticle tracking analysis. d Representative images of Western blot showing the exosomal protein markers. e Representative confocal images showing that red fluorescence dye PKH26-labeled Exo (Exo-PKH26) were endocytosed by MSCs after12-h incubation. Scale bar = 60 μm. f Distribution of Exo-PKH26 in the infarcted heart on day 1, day 3, and day 7 post injection. Scale bar = 50 μm. g Quantification of PKH26+ cells in f (n = 5). (A-G) n = 5. All data are mean ± SEM. Statistical analysis was performed with one-way ANOVA followed by Tukey’s test. **p < 0.01, ****p < 0.0001

Combined Exo and MSC transplantation improved post AMI cardiac function

To determine the potential effect of combinatory delivery of Exo and MSCs in vivo, Exo or PBS was intramyocardially injected into the border zone of infarcted rat hearts 30 min after injury. In consideration of different retention rate of Exo and the possible functional outcome it may cause, we designed experiments where MSCs were injected into the rats through the tail vein at 1 day, 3 days, or 7 days post AMI-Exo treatment (Fig. 2a). While AMI weakened the contractility of left ventricle (LV) anterior walls compared to Sham operation, Exo and MSC combined delivery significantly mitigated AMI-induced LV dilation on day 35 (Fig. 2b). In the AMI control group, a significant decrease in LVEF and LVFS were observed, suggesting compromised cardiac function. Delivery of Exo alone gave rise to increase in LVEF and LVFS and significant decrease in LVESV but not in LVEDV. Delivery of MSCs alone at 7 days after MI showed significant improvement in LV contractility and function. We then explored the optimal time window for combined Exo and MSC delivery (Fig. 2c–f). In combination of Exo administered on the day of MI (d0), no further improvement of heart function was found if MSCs were injected on day 1 (Exo + MSCd1) compared to groups treated with either Exo or MSCs alone. In contrast, delivery of MSCs on day 3 (Exo + MSCd3) and day 7 (Exo + MSCd7) resulted in a further improvement of both LVEF and LVFS over other groups (Fig. 2c, d). MSCs injected 3 days after Exo delivery (Exo + MSCd3) achieved the best improvement of cardiac function among all three combination groups, although no statistically significant relationship was found (Fig. 2c–f).

Fig. 2
figure2

Exo and MSCs synergistically improved cardiac function and ameliorated fibrosis after AMI. a Schematic of the sequential delivering of Exo followed by MSCs into the infarcted hearts experiment. b Representative echocardiogram of rat hearts in different groups 5 weeks post AMI. c, f Significantly enhanced left ventricular ejection fraction (LVEF), fractional shortening (LVFS), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) in rats co-transplanted with Exo and MSCs compared with AMI, Exo, and MSCs alone groups (n = 6–8 for each group). g Representative transverse heart sections analyzed with Masson trichrome staining at 5 weeks after AMI. Red, myocardium; blue, scarred fibrosis. Scale bar = 2 mm. h Representative Sirius Red staining images for collagen analyze in each group. Scale bar = 2 mm. i, j Quantitative data for the LV fibrotic area and the quantitative data of Masson trichrome staining (i) and Sirius Red staining (j) (n = 6–8 for each group). All data are mean ± SEM. Statistical analysis was performed with two-way ANOVA followed by Tukey post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. AMI group; #p < 0.05, ##p < 0.01, ###p < 0.01 vs. Exo group; $p < 0.05, $$p < 0.01, $$$$p < 0.0001 vs. MSC group; &p < 0.05 vs. Exo + MSCd7 group

Because Exo and MSCs combinatorial treatment groups demonstrated preserved cardiac function, we were interested to evaluate the infarct size and collagen area. At 5 weeks post infarction, all of the Exo and MSC alone groups showed no significant decrease in infarct size when compared with AMI control group. In contrast, rat hearts receiving Exo and MSC combinatorial treatment had significantly smaller infarct size. Importantly, the reduction in infarct size was more prominent in Exo + MSCd3 group when compared with that in Exo alone and Exo + MSCd7 group (Fig. 2g, i). Consistent with the echocardiogram results, collagen area decreased significantly in all of the therapeutic groups, but the infarcted hearts treated with MSCs at day 3 followed by Exo delivery demonstrated further decreased collagen area compared with those in the MSCd3 group (Fig. 2h, j). Of note, Exo + MSCd3 group achieved the lowest infarct area and collagen positive area among all three combination groups (Fig. 2i, j). Together, these results indicated that Exo and MSC combinatorial treatment after AMI resulted in an enhanced therapeutic effect, and 3 days after MI-Exo treatment might be the best time point for sequential stem cells delivery.

Exo and MSC combinatorial therapy augmented neovascularization and myocyte survival after AMI

To investigate whether Exo and MSC combinatorial therapy induces morphometric changes in the infarcted heart, we assessed vascular density in peri-infarct myocardium by quantification of α-SMA staining on the smooth muscle lining arterioles, and CD 31 staining on the luminal side of vascular endothelial cells (Fig. 3). Exo and MSC alone groups failed to increase arteriolar density when compared with AMI group. In contrast, arteriolar density was significantly increased by the Exo and MSC combinatorial treatment. Comparing the three combinatory treatment groups, Exo + MSCd3 showed the highest increase in microvascular density compared with Exo + MSCd1 and Exo + MSCd7. This increase in microvascular density was observed in both arteriolar and capillary vessels (Fig. 3a–d). Increased capillary density was also found in Exo and MSCd7 alone groups while there was no significant change in MSCd1 and MSCd3 groups (Fig. 3c, d).

Fig. 3
figure3

Exo and MSCs combined therapy promoted angiogenesis in the infarcted hearts. a Arterioles at the border zone on 5 weeks after AMI were identified by staining with α-SMA (green) and nuclei (blue). b Quantification of α-SMA+ cells in A (n = 5). c Capillary at the border zone on 5 weeks after AMI was identified by staining with CD31 (green) and nuclei (blue). d Quantification of CD31+ cells in c (n = 5). All data are mean ± SEM. Statistical analysis was performed with two-way ANOVA followed by Tukey post hoc test. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. AMI group; ##p < 0.01, ####p < 0.0001 vs. Exo group; $$p < 0.01, $$$p < 0.001, $$$$p < 0.0001 vs. MSC group; &&p < 0.01, &&&&p < 0.0001 vs. Exo + MSCd1 and Exo + MSCd7 groups. Scale bar = 50 μm

Exo adapted cardiac environment through reducing inflammation and enhancing SDF-1 expression to improve MSCs recruitment and retention

To better elucidate the mechanisms underlying the hemodynamic and morphometric improvements observed by the Exo and MSCs combined therapy, we evaluated the distribution and recruitment/retention of transplanted MSCs in infarcted myocardium through fluorescent dye tracing. We transplanted CM-Dil-labeled MSCs to the MI rat hearts at day 1, day 3, or day 7 with or without additional treatment with PKH67 pre-labeled Exo. Heart sections in these animals at 5 weeks post MI were analyzed and we found that significant more CM-Dil+ cells were found in Exo and MSC combinatorial treatment groups compared to MSC alone groups. In addition, CM-Dil+ cells were significantly increased in Exo + MSCd3 hearts compared with Exo + MSCd1 (1.7-fold) and Exo + MSCd7 hearts (1.8-fold, Fig. 4a, b). Collectively, these results indicated that retention of transplanted MSCs in the myocardium could be achieved when Exo was delivered on the day of MI injury followed by MSC delivery at day 3 after Exo injection.

Fig. 4
figure4

Exo pretreatment provided a relatively low inflammatory reaction and relatively high level of SDF-1 micro-environment in infarcted hearts for transplanted MSCs to survive. a Distribution of MSCs pre-labeled with CM-Dil (red) in the infarcted hearts on 5 weeks post AMI in the groups with and without PKH67 pre-labeled Exo (green) injection. Scale bar = 100 μm. b Quantification of CM-Dil+ cells in A (n = 5). c Representative HE staining images at the border zone 5 weeks after AMI. Scale bar = 200 μm. d, e Quantification of IL-6 and TNF-α expression level in the infarct border zone tissue of rat hearts using ELISA method (n = 5). f Representative immunohistochemical staining images of SDF-1 in PBS and Exo groups in 1 day, 3 days, and 7 days post AMI (× 200). Scale bar = 200 μm. g ELISA assessment of SDF-1 expression during the time course. All data are mean ± SEM. Statistical analysis was performed with one-way ANOVA followed by Tukey’s test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ##p < 0.01, ###p < 0.001

Severe inflammation in myocardial microenvironment post MI is detrimental to the survival of transplanted cells. Since the interaction between SDF-1and CXCR4 plays a vital role in the engraftment of MSCs in the injured myocardium [6, 9], we therefore determined the inflammation level and SDF-1 expression in infarcted hearts to further investigate potential mechanisms underlying the enhanced migration/retention observed in the day 3 MSC combinatorial therapy group. H&E staining demonstrated that massive inflammatory cell infiltration occurred in infarcted hearts during the first week post AMI and that Exo delivery significantly reduced immune cell infiltration at day 3 and day 7 post MI compared to the PBS group (Fig. 4c). Furthermore, ELISA test showed that cytokines such as IL-6 and TNF-α in peri-infarcted heart tissue were decreased significantly compared to the PBS control group on 3 days after Exo delivery (Fig. 4d, e). Thus, the delivered Exo played a potent regulatory role in reducing inflammation in the ischemic myocardium post MI.

Consistent with previous report [8,9,10], both immunohistochemistry (Fig. 4f) and ELISA (Fig. 4g) results showed that SDF-1 expression in peri-infarcted heart tissue of PBS control group peaked at day 1 post AMI and rapid declined within the first week. In contrast, SDF-1 maintained a relatively high level of expression in Exo transplanted hearts on day 3 post AMI and dropped to a similar level on day 7 as PBS group. Therefore, administration of Exo offered longer time window of maintained upregulation of SDF-1 expression post AMI. Taken together, intramyocardial injection of Exo led to a lower inflammation level and relatively high SDF-1 expression in peri-infarcted myocardium on day 3 after AMI, which probably contributed to the higher recruitment and retention rate of MSCs in the Exo + MSCd3 combinatorial therapy group.

Exo protects MSC against H/SD and reduced apoptosis both in vitro and in vivo

To determine the effect of Exo on MSC survival, MSCs were treated with Exo for 12 h and then subjected to H/SD in vitro. Flow analyses showed that the H/SD + Exo group demonstrated a significant reduction in apoptosis compared to the H/SD and H/SD + Exo (Ultra) groups, in which exosomes were ruptured by ultrasonic (Fig. 5a, b). Similar result was observed using Hoechst 33342 staining assay (Fig. 5c, d). Interestingly, Exo treatment enhanced the expression of anti-apoptotic protein Bcl-2 in MSCs under H/SD (Fig. 5e, f), which may protect cells from cell death. These results indicated that Exo significantly improved the survival of the MSCs under hypoxic stress.

Fig. 5
figure5

Exo enhanced the survival and decreased the apoptosis of MSCs under hypoxia and serum deprivation (H/SD) conditions. ad Flow cytometry assay and Hoechst 33342 nucleic acid stain for apoptosis of MSCs after treated with PBS, Exo, or Exo (Ultra) and exposed to H/SD. a Scatter diagram of apoptosis in MSCs treated with Exo and negative control. b Histogram of apoptosis events in different groups (n = 3). c Representative images of Hoechst 33342 nucleic acid stain. Scale bar = 100 μm. d Quantification of apoptosis cells in each group (n = 3). e Western blot for Bcl-2 protein in MSCs treated with Exo or Exo (Ultra) and exposed to H/SD condition. f Quantification of Bcl-2 in E (n = 3). g TUNEL staining at the border zone on 5 weeks post AMI with TUNEL (green) and nuclei (blue). h Quantification of TUNEL+ cells in G (n = 5). Apoptosis rate was quantified as the percentage of cells that were positive for TUNEL staining. All data are mean ± SEM. Statistical analysis was performed with one-way ANOVA followed by Tukey’s test or two-way ANOVA followed by Tukey post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. H/SD or AMI group; ###p < 0.001 vs. Exo group; $p < 0.05, $$p < 0.01 vs. H/SD + Exo or MSC group; &p < 0.05 vs. Exo + MSCd1 group. Scale bar = 50 μm

To further explore the pro-survival effect of Exo and MSC combined therapy in vivo, TUNEL staining was performed in the treated hearts on 5 weeks post MI. The number of apoptotic cells was significantly decreased in the myocardial boarder zone treated with exosomes or MSCs compared to that treated with PBS. Among the three combination therapy groups, only the Exo + MSCd3 group was found to statistically further reduce the number of TUNEL+ cells compared with Exo and MSCs alone groups. Importantly, the apoptotic cells also significantly decreased in day 3 combination group when compared with day 1 combination group (Fig. 5g, h). Taken together, these results indicated that pre-treatment with Exo can enhance the ability of MSCs to survive under the H/SD condition in vitro and the ischemic environment in vivo, which may in turn contribute to the improved cardiac function post AMI.

Discussion

Despite the promise shown by various types of stem cells for restoration of cardiac function after AMI, the low recruitment and poor survival of transplanted cells have been a major issue [2, 3, 7]. Delivery of cell-free components, such as exosomes derived from stem cells, has been demonstrated to enhance myocardial viability and reduce or slow down the adverse remodeling of pathological hearts [14, 20]. Therefore, we reasoned that administration of MSC-derived exosomes would modulate the ischemic milieu to facilitate transplantation of stem cells and thus could achieve better cardiac repair/regeneration. This study showed a further improved therapeutic efficacy of sequential delivery of MSCs following Exo injection in a rat AMI model and revealed multifaceted mechanisms that enhanced recruitment and survival of co-transplanted MSCs. Of note, we further demonstrated that 3 days after Exo delivery into infarcted hearts was the optimal time point when the microenvironment is less inflammatory and tolerable for the stem cells to be retained in the ischemic hearts (Fig. 6).

Fig. 6
figure6

Effects and mechanisms of MSC-derived exosomes and MSC combinatorial therapy on acute myocardial infarction. Delivery of Exo into infarcted hearts 30 min post AMI can significantly reduce inflammatory factors such as IL-6 and TNF-α, increase SDF-1 expression and angiogenesis, and promote cell survival in the stressed ischemic microenvironment at day 3 post AMI. These mechanisms ultimately lead to significant augmentation of cardiac function and reducing scar size of AMI rat hearts after Exo and stem cells combinatorial therapy

Recent studies have suggested that MSC-derived exosomes carry a wide range of functional proteins, mRNAs, and miRNAs which could serve as a potential cell-free therapeutic for cardiac repair [17, 18, 28]. However, exosomes therapy hardly achieved the goal of myocardial regeneration and/or sustained functional restoration because they lack the ability to promote cardiomyocyte proliferation and regeneration [19, 29]. In addition, the exosome therapy has a short effective lifetime and mild efficacy due to limited retention in the myocardium [19, 29, 30]. In this study, we injected exosomes 30 min after MI and then cells at intervals of 1, 3, and 7 days post MI. Such kind of combined treatment of exosomes with stem cells may be a more viable therapeutic approach for clinical cardiac regeneration. Although a 30-min interval for door to balloon time is too short for clinical application, which is a limitation of this study, this scheme provides reference for the design of future large animal experiments and clinical trials. To our knowledge, this is the first known report of a combinatorial therapy using both stem cell-derived exosome and stem cells in the ischemic myocardium.

One of the main barriers limiting the effectiveness of stem cell transplantation is the stress ischemic microenvironment in which high level of inflammation would damage most of the transplanted cells. To avoid the adverse inflammation during the first few days post AMI, most studies transplanted stem cells 1 to 2 weeks after AMI [3, 31]. However, emerging evidence and our results suggested that the expression of SDF-1, which plays a vital role on MSC migration and survival, increased rapidly within 1 to 3 days post AMI and subsequently decreased to the background level in the following week [8,9,10] (Fig. 4f, g). These dynamic changes of inflammation and SDF-1 expression make it challenging to identify an optimal intervention time of stem cells and lead to a low recruitment and survival of transplanted cells [11]. In this study, we nstead pre-delivered Exo 3 days before MSC transplantation to alleviate heart injury. This approach created a less inflammatory microenvironment where inflammation was downregulated while SDF-1 remained at relatively high level. This strategy of combinatorial therapy demonstrated higher recruitment and retention rate of transplanted cells as well as superior recovery of heart function.

Exosomes affect stem cell functions in multiple ways. Zhang et al. [32] preconditioned cardiac progenitor cells (CPCs) with MSC-derived exosomes and then transplanted the pretreated CSCs into a rat MI model. They found that the pretreatment of CSCs with Exo had a superior effectiveness in decreasing cardiac fibrosis and increasing survival and capillary density, which finally improved cardiac function. Ong et al. [33] co-delivered exosomes derived from endothelial cells (EC-Exo) with CPCs into MI mice and demonstrated that CPCs are capable of uptaking EC-Exo in 12 h after injection, which could confer increased tolerance to the co-transplanted CPCs at day 7. In our study, we found that prior treatment with Exo rendered MSCs increased tolerance to hypoxia stress both in vitro and in vivo, indicating a consistent positive interaction between stem cell-derived exosomes and stem cells.

In recent years, various novel strategies have been designed and studied to enhance stem cell-based therapies including cell pretreatment, genetic modification, biomaterial approach, and combination cell therapy [20, 34]. We presented here sequential delivery of stem cell-derived exosomes followed by stem cell further improved heart function. These advances demonstrate the promising potential of stem cell therapy, while the goal of full cardiac recovery and regeneration has yet to be realized in either preclinical or clinical researches. Continuing efforts to discover novel multifaceted cell-based therapeutic approaches, such as incorporation of stem cells and exosomes into biomaterials and loading exosomes or stem cells with cell fate reprogramming factors, could accelerate our progress to achieve this goal.

Conclusions

Combinatorial delivery of exosomes and stem cells in a sequential manner effectively reduces scar size and restores heart function after AMI. Delivery of Exo into infarcted hearts 30 min post AMI can significantly reduce inflammatory factors such as IL-6 and TNF-α, increase SDF-1 expression and angiogenesis, and promote stem cell survival in the stressed ischemic microenvironment at day 3 post AMI. This approach may represent as an alternative promising strategy for stem cell-based heart repair and therapy (Fig. 6).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Abbreviations

AMI:

Acute myocardial infarction

CPCs:

Cardiac progenitor cells

CXCR4:

CXC chemokine receptor 4

EC:

Endothelial cell

ESCs:

Embryonic stem cells

Exo:

Exosomes derived from MSCs

FBS:

Fetal bovine serum

FS:

Fractional shortening

H/SD:

Hypoxia and serum deprivation

IL-6:

Interleukin 6

iPSCs:

Induced pluripotent stem cells

LVEDV:

Left ventricular end-diastolic volume

LVEF:

Left ventricular ejection fraction

LVESV:

Left ventricular end-systolic volume

MSCs:

Mesenchymal stem cells

PBS:

Phosphate-buffered saline

SDF-1:

Stromal cell-derived factor 1

TEM:

Transmission electron microscopy

TNF-α:

Tumor necrosis factor-α

α-SMA:

Smooth muscle α-actin

References

  1. 1.

    Global Health Estimates 2016. Deaths by cause, age, sex, by country and by region, 2000-2016. Geneva: World Health Organization; 2018.

  2. 2.

    Tompkins BA, Balkan W, Winkler J, Gyongyosi M, Goliasch G, Fernandez-Aviles F, et al. Preclinical studies of stem cell therapy for heart disease. Circ Res. 2018 2018;122(7):1006–20.

  3. 3.

    Pavo N, Charwat S, Nyolczas N, Jakab A, Murlasits Z, Bergler-Klein J, et al. Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. J Mol Cell Cardiol. 2014;75:12–24.

  4. 4.

    Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, et al. Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ Res. 2015;117(6):558–75.

  5. 5.

    Dong F, Harvey J, Finan A, Weber K, Agarwal U, Penn MS. Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Circulation. 2012;126(3):314–24.

  6. 6.

    Zaruba MM, Franz WM. Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy. Expert Opin Biol Ther. 2010;10(3):321–35.

  7. 7.

    Yang D, Sun S, Wang Z, Zhu P, Yang Z, Zhang B. Stromal cell-derived factor-1 receptor CXCR4-overexpressing bone marrow mesenchymal stem cells accelerate wound healing by migrating into skin injury areas. Cell Reprogram. 2013;15(3):206–15.

  8. 8.

    Mayorga ME, Kiedrowski M, McCallinhart P, Forudi F, Ockunzzi J, Weber K, et al. Role of SDF-1:CXCR4 in impaired post-myocardial infarction cardiac repair in diabetes. Stem Cells Transl Med. 2018;7(1):115–24.

  9. 9.

    Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362(9385):697–703.

  10. 10.

    Ma J, Ge J, Zhang S, Sun A, Shen J, Chen L, et al. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol. 2005;100(3):217–23.

  11. 11.

    Chen Y, Teng X, Chen W, Yang J, Yang Z, Yu Y, et al. Timing of transplantation of autologous bone marrow derived mesenchymal stem cells for treating myocardial infarction. Sci China Life Sci. 2014;57(2):195–200.

  12. 12.

    Li J, Guo W, Xiong M, Han H, Chen J, Mao D, et al. Effect of SDF-1/CXCR4 axis on the migration of transplanted bone mesenchymal stem cells mobilized by erythropoietin toward lesion sites following spinal cord injury. Int J Mol Med. 2015;36(5):1205–14.

  13. 13.

    Hajinejad M, Pasbakhsh P, Omidi A, Mortezaee K, Nekoonam S, Mahmoudi R, et al. Resveratrol pretreatment enhanced homing of SDF-1alpha-preconditioned bone marrow-derived mesenchymal stem cells in a rat model of liver cirrhosis. J Cell Biochem. 2018;119(3):2939–50.

  14. 14.

    Poe AJ, Knowlton AA. Exosomes as agents of change in the cardiovascular system. J Mol Cell Cardiol. 2017;111:40–50.

  15. 15.

    Cervio E, Barile L, Moccetti T, Vassalli G. Exosomes for intramyocardial intercellular communication. Stem Cells Int. 2015;2015:482171.

  16. 16.

    Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4(3):214–22.

  17. 17.

    Yu B, Kim HW, Gong M, Wang J, Millard RW, Wang Y, et al. Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection. Int J Cardiol. 2015;182:349–60.

  18. 18.

    Khan M, Nickoloff E, Abramova T, Johnson J, Verma SK, Krishnamurthy P, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res. 2015;117(1):52–64.

  19. 19.

    Dougherty JA, Mergaye M, Kumar N, Chen CA, Angelos MG, Khan M. Potential role of exosomes in mending a broken heart: nanoshuttles propelling future clinical therapeutics forward. Stem Cells Int. 2017;2017:5785436.

  20. 20.

    Huang P, Tian X, Li Q, Yang Y. New strategies for improving stem cell therapy in ischemic heart disease. Heart Fail Rev. 2016;21(6):737–52.

  21. 21.

    Li N, Yang YJ, Qian HY, Li Q, Zhang Q, Li XD, et al. Intravenous administration of atorvastatin-pretreated mesenchymal stem cells improves cardiac performance after acute myocardial infarction: role of CXCR4. Am J Transl Res. 2015;7(6):1058–70.

  22. 22.

    Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;3:3–22.

  23. 23.

    Atay S, Gercel-Taylor C, Kesimer M, Taylor DD. Morphologic and proteomic characterization of exosomes released by cultured extravillous trophoblast cells. Exp Cell Res. 2011;317(8):1192–202.

  24. 24.

    Li Q, Dong QT, Yang YJ, Tian XQ, Jin C, Huang PS, et al. AMPK-mediated cardioprotection of atorvastatin relates to the reduction of apoptosis and activation of autophagy in infarcted rat hearts. Am J Transl Res. 2016;8(10):4160–71.

  25. 25.

    Enomoto D, Obana M, Miyawaki A, Maeda M, Nakayama H, Fujio Y. Cardiac-specific ablation of the STAT3 gene in the subacute phase of myocardial infarction exacerbated cardiac remodeling. Am J Physiol Heart Circ Physiol. 2015;309(3):H471–80.

  26. 26.

    Rota M, Kajstura J, Hosoda T, Bearzi C, Vitale S, Esposito G, et al. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci USA. 2007;104(45):17783–8.

  27. 27.

    Tang JM, Wang JN, Zhang L, Zheng F, Yang JY, Kong X, et al. VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res. 2011;91(3):402–11.

  28. 28.

    Bian S, Zhang L, Duan L, Wang X, Min Y, Yu H. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. J Mol Med (Berl). 2014;92(4):387–97.

  29. 29.

    Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119(1):91–112.

  30. 30.

    Chen CW, Wang LL, Zaman S, Gordon J, Arisi MF, Venkataraman CM, et al. Sustained release of endothelial progenitor cell-derived extracellular vesicles from shear-thinning hydrogels improves angiogenesis and promotes function after myocardial infarction. Cardiovasc Res. 2018;114(7):1029–40.

  31. 31.

    Wu T, Xie Y, Huang J, Li P, Wang X, Yan Y, et al. The optimal intervention time of bone marrow mesenchymal stem cells in ameliorating cardiac fibrosis induced by viral myocarditis: a randomized controlled trial in mice. Stem Cells Int. 2017;2017:3258035.

  32. 32.

    Zhang Z, Yang J, Yan W, Li Y, Shen Z, Asahara T. Pretreatment of cardiac stem cells with exosomes derived from mesenchymal stem cells enhances myocardial repair. J Am Heart Assoc. 2016;5(1):e2856.

  33. 33.

    Ong SG, Lee WH, Huang M, Dey D, Kodo K, Sanchez-Freire V, et al. Cross talk of combined gene and cell therapy in ischemic heart disease: role of exosomal microRNA transfer. Circulation. 2014;130(11 Suppl 1):S60–9.

  34. 34.

    Mayfield AE, Tilokee EL, Davis DR. Resident cardiac stem cells and their role in stem cell therapies for myocardial repair. Can J Cardiol. 2014;30(11):1288–98.

Download references

Acknowledgements

We thank Drs. Yang Zhou, Hong Ma, and Ziqing Liu at the University of North Carolina at Chapel Hill for their scientific advices. We also thank Peihe Wang in the Experimental Animal Center of Fuwai Hospital and Qing Xu of Central Laboratory of Capital University of Medical Sciences for their technical assistance.

Funding

This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) [grant number 2016-12 M-1-009], Innovative Research Foundation of Peking Union Medical College [grant number 2016-1002-01-03], grants from National Natural Science Foundation of China [grant numbers 81370223, 81573957 and 81670337], National Science and Technology Major Project of the Ministry of Science and Technology of China [grant number 2014ZX09101042001], China Postdoctoral Science Foundation Grant [grant number 2019TQ0380], and the program of China Scholarships Council [No. 201706210393].

Author information

PH, YY, and LQ have substantial contributions to the conception or design of the work; PH, LW, QL, and JX contributed to the data collection; J-YX, YX, and GC did the data analysis and interpretation; PH, HQ, CJ, and YY drafted the manuscript; JL, LQ, and YY contributed to the critical revision of the manuscript. All authors read and approved the final manuscript.

Correspondence to Li Qian or Yuejin Yang.

Ethics declarations

Ethics approval and consent to participate

The experimental procedures in this experiment to animals were under the institutionally approved protocols of animal research at Fuwai Hospital, Chinese Academy of Medical Sciences (20151124-R-154-ZXYN-863).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Exosomes
  • MSCs
  • SDF-1
  • Myocardial infarction